|
NATURE April 15, 1961
Vol 190
No. 4772
pp263-234
GASTRO-INTESTINAL ABSORPTION OF HEPARIN
AND SYNTHETIC HEPARINOIDS
HEPARIN and synthetic
heparinoids have to be administered parenterally to assure clinical efficacy.
Since oral administration of these drugs would be highly desirable, numerous
compounds were tested for their ability to effect absorption from the
gastrointestinal tract. The criterion of absorption was the appearance
of plasma lipemia-clearing activity, which was first described by Hahn.
Several compounds (adjuvants) were discovered to have this
property, the best of these being certain salts of ethylenediaminetetraacetic
acid (EDTA). [Emphasis added.] Other active compounds will be the
subjects of future communications. The present communication describes
the use of salts of EDTA to obtain absorption of heparin and synthetic
heparinoids.
Rats weighing about 200gm were placed in individual cages
and fed for 72hr. a liquid diet consisting of 30ml. of a 33 percent casein
hydrolysate and water ad lib. The drug was given by intubation
of aqueous solution at a volume of 10ml/kgm.
Table 1. Rat and Dog Lipemia-Clearing Activity 4 hr.
after
Oral Sulphopolyglucin Plus EDTA
|
Animal
|
Number of
Animals
|
SPG
(mgm/kgm)
|
Sodium salt
Of EDTA
(mgm/kgm)
|
Lipemia-clearing
Activity (C.U.*)
|
|
Rats
|
5*
5
4
|
500
500
---
|
---
500
500
|
0.04 ± 0.03
2.41 ± 0.74
0.01 ± 0.01
|
|
Dogs
|
5
6
|
100
100
|
---
50
|
0.59 ± 0.41
5.73 ± 1.04
|
*Means ± standard deviation
=====================================================================================
Table 2. Lipemia-Clearing Activity and Clotting Time After
oral Heparin Plus EDTA in Rats and Dogs
|
Rats
|
Dogs
|
|
Heparin 50 mgm/kgm
Sodium salt of EDTA 500 mgm/kgm
|
Heparin 100 mgm/kgm
Sodium salt of EDTA 50 mgm/kgm
|
|
Time (min)
|
ClringActv(CU*)
|
Clotting time (min)
|
Time (hr)
|
ClringActv(CU*)
|
Cltgtime(min)
|
|
0
10
30
60
|
0.04 ± 0.03 (5)
0.10 ± 0.09 (3)
1.46 ± 0.17 (3)
0.31 ± 0.24 (3)
|
7.0 ± 1.7 (16)
11.0 ± 1.3 (3)
13.3 (2)
8.0
(1)
|
0
1
2
4
|
0.19 ± 0.18 (4)
0.85 ± 0.70 (4)
0.99 ± 0.66 (4)
0.31 ± 0.45 (4)
|
11.3 ± 2.1 (8)
> 28 ± 21 (8)
> 44 ± 22 (8)
18.1 ± 8.2 (8)
|
Figures in parentheses are number of animals. >, some animals had
incoagulable blood (> 60 min) *, mean ± standard deviation.
=====================================================================================================
At specified times, the rats were anesthetized with pentobarbital sodium,
and blood samples taken by cardiac puncture.
In dogs, after an overnight fast, the drugs were given orally in gelatin
capsules. Blood samples were taken by venipuncture at specified intervals.
Lipemia-clearing activity of citrated plasma was determined and expressed
in clearing units (C.U.) calculated according to Grossman, except that
incubation time was limited to 10 minutes and the substrate was Ediol
(SchenLabs), diluted 1 to 50 with water. Whole-blood clotting time was
determined by a three-tube Lee-White method and indicated in minutes.
When blood did not clot within 60 min, a value of 60 min was used in
calculating mean clotting time, but the > sign was added.
All values for clearing activity and clotting time are given as mean
± standard deviation for groups of 5-10 animals or as specified.
The drugs used were heparin sodium U.S.P., potassium salt of sulphopolyglucin
(SPG) and various salts of EDTA. SPG is a sulphated polysaccharide
[Emphasis added.] of 5 to 15 glucose units connected by a,
1-4, and a, 1-6 linkages, with 2-3 sulphate groups per glucose unit.
Typical experiments demonstrating the adjuvant property of sodium EDTA
are presented in Table 1. Using lipemia-clearing activity as an index
of absorption, the result show, without a question, the adjuvant properties
of sodium EDTA. In dogs, where SPG alone produces measurable although
somewhat erratic clearing activity, absorption of the heparinoid is
increased about ten-fold by simultaneous administration of
the sodium salt of EDTA. [Emphasis added.] In rats, the effect of
EDTA is even greater, since SPG alone is practically not absorbed.
Similar results with SPG have been found in every animal species studied
(monkey, dog, cat, rabbit, and rat), as well as in man. The adjuvant
property of EDTA has also been demonstrated for other synthetic heparinoids
[Emphasis added.] (polyethylene sulphonate, dextran sulphate and others).
The adjuvant property [Emphasis added.] of the sodium salt of
EDTA [Emphasis added.] can also be demonstrated for heparin,
using both clotting time and clearing activity [Emphasis added.]
as criteria of absorption (Table 2).
The effects of EDTA are again unequivocal. In rats, clearing activity
reached a peak about 30 min. after administration of the drug combination,
and then declined slowly to control-levels. A similar time course was
obtained for the anti-coagulant effect, with doubling of the clotting
[Emphasis added.] time at about 30 min. after the drug and subsequent
return to control-levels. Since it is known that heparin is not absorbed
from the gastro-intestinal tract, control experiments without EDTA were
not made.
In dogs, the typical heparin effects appeared slower than in the rates.
The peak of clearing activity and anti-coagulant effects were reached
about 2 hr. after drug combination and returned to control-levels after
more than 4 hr.
Further experiments were carried out in dogs to establish dose-response
curves for SPG, both with and without EDTA. The results in Fig. 1 show
good correlation between dose and clearing as well as anti-coagulant
activity. Statistical evaluation indicated that the efficacy of SPG
was increased approximately five-fold when EDTA, in the ratio 1:4, was
used as adjuvant. [Emphasis added.]
Significant amounts of heparin and synthetic heparinoids can be absorbed
from the gastro-intestinal tract when these drugs are given orally
together with an alkali salt of EDTA. The mechanism of this adjuvant
effect is not clear. [Emphasis added.] There is evidence that the
Chelation of calcium and/or magnesium ions of EDTA may be involved for
the following reasons: (1) Sodium, potassium and ammonium salts of EDTA
are effective as adjuvants; #2) calcium and magnesium EDTA are not effective;
(3) adding a calcium salt blocks the adjuvant action of alkali EDTA;
(4) phosphate buffers are not effective; (5) the adjuvant has to be
given orally; intravenous injection of the adjuvant does not influence
the absorption of SPG from the gastro-intestinal tract.
E. Windsor
G.E. Cronheim
Riker Laboratories, Inc.
Northridge California
__________________________________
1 Loomis, T.A., Pharmacology in Medicine, edit, By
Drill, V.A., second ed. (Blakiston, New York, 1958).
2 Hahn, P.F., Science, 98, 10 (1943).
3 Groossman, M.I., J.Lab. Clin. Med., 43, 445 (1954).
4 Lee, R.I., and White, P.D., Amer.J.Med.Sci., 145 405 (1913).
5 Seldell, M.A., Windsor, E., and Surtshin, A., Clin.Res.,8, 246
(1960).
|